Risk assessment models for cancer‐associated venous thromboembolism
Venous thromboembolism (VTE) is common in cancer patients, and is associated with
significant morbidity and mortality. Several factors, including procoagulant agents secreted …
significant morbidity and mortality. Several factors, including procoagulant agents secreted …
[引用][C] Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update summary
NS Key, K Bohlke, A Falanga - Journal of oncology practice, 2019 - ascopubs.org
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO
Clinical Practice Guideline Update Summary | JCO Oncology Practice Skip to main content …
Clinical Practice Guideline Update Summary | JCO Oncology Practice Skip to main content …
Cancer-associated thrombosis
GC Connolly, CW Francis - Hematology 2013, the American …, 2013 - ashpublications.org
Cancer-associated thrombosis accounts for almost one-fifth of all cases of venous
thromboembolism (VTE) and is a leading cause of death, morbidity, delays in care, and …
thromboembolism (VTE) and is a leading cause of death, morbidity, delays in care, and …
[HTML][HTML] Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
AJ Munoz Martin, I Ortega, C Font, V Pachón… - British journal of …, 2018 - nature.com
Background Venous thromboembolism (VTE) is a leading cause of death among patients
with cancer. Outpatients with cancer should be periodically assessed for VTE risk, for which …
with cancer. Outpatients with cancer should be periodically assessed for VTE risk, for which …
Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score
MA De Winter, JAN Dorresteijn… - Thrombosis and …, 2022 - thieme-connect.com
Background Bleeding risk is highly relevant for treatment decisions in cancer-associated
thrombosis (CAT). Several risk scores exist, but have never been validated in patients with …
thrombosis (CAT). Several risk scores exist, but have never been validated in patients with …
COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment …
Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …
Prediction of venous thromboembolism in cancer patients
The risk of venous thromboembolism (VTE) is increased in cancer patients. To improve
prediction of VTE in cancer patients, we performed a prospective and observational cohort …
prediction of VTE in cancer patients, we performed a prospective and observational cohort …
[HTML][HTML] Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry …
N Kucher, D Spirk, I Baumgartner, L Mazzolai, W Korte… - Annals of oncology, 2010 - Elsevier
Background: Venous thromboembolism (VTE) prophylaxis remains underutilized,
particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized …
particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized …
The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment
A Falanga - Cancer investigation, 2009 - Taylor & Francis
Patients with cancer are at high risk of developing venous thromboembolism, a risk that
varies according to the type of malignancy and its disease stage, and is steadily increased …
varies according to the type of malignancy and its disease stage, and is steadily increased …
[PDF][PDF] Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients
MB Streiff - Clin Adv Hematol Oncol, 2013 - hematologyandoncology.net
Nearly 20% of all venous thromboembolism (VTE) occurs in cancer patients, and as many
as 78% of cancer patients who develop a thrombotic event do so as outpatients. The risk of …
as 78% of cancer patients who develop a thrombotic event do so as outpatients. The risk of …